In vitro activity of antifungals against zygomycetes

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 71-76

  Alastruey Izquierdo, A ^a   Castelli, M V ^a   Cuesta, I ^a   Zaragoza, O ^a   Monzon A ^a   Mellado, E ^a   Rodriguez Tudela J L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antifungal; In vitro activity; Mucormycosis; Zygomycetes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ABSIDIA; ANTIFUNGAL SUSCEPTIBILITY; COKEROMYCES RECURVATUS; CUNNINGHAMELLA BERTHOLLETIAE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCOR CIRCINELLOIDES; MUCOR RAMOSISSIMUS; MUCORMYCOSIS; MYCOCLADUS CORYMBIFER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHIZOMUCOR; RHIZOMUCOR PUSILLUS; RHIZOPUS; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; SAKSENAEA VASIFORMIS; SALVAGE THERAPY; SURVIVAL RATE; SYNCEPHALASTRUM RACEMOSUM; ZYGOMYCETES;

ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUCORALES; MUCORMYCOSIS; PYRIMIDINES; TRIAZOLES;

EID: 70349983825     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02984.x     Document Type: Review

References (64)

1. Butala A, Shah B, Cho YT, Schmidt MF. Isolated pulmonary mucormycosis in an apparently normal host: a case report. J Natl Med Assoc 1995, 87:572-574.
2. Zeilender S, Drenning D, Glauser FL, Bechard D. Fatal Cunninghamella bertholletiae infection in an immunocompetent patient. Chest 1990, 97:1482-1483.
3. Park SK, Jung H, Kang MS. Localized bilateral paranasal mucormycosis: a case in an immunocompetent patient. Acta Otolaryngol 2006, 126:1339-1341.
4. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
5. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45-52.
6. Greenberg RN, Mullane K, van Burik JA. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
7. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
8. Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary care cancer centre in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
9. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:2587-2590.
10. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006, 50:917-921.
11. Reference Method for Broth Dilution Antifungal Susceptibility. Testing of Filamentous Fungi 2005, Approved Standard Document M38-A
12. Tudela JLR, Donnelly JP, Arendrup MC. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 2008, 14:982-984.
13. Aberkane A, Cuenca-Estrella M, Gomez-Lopez A. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother 2002, 50:719-722.
14. Petrikkou E, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez A, Molleja A, Mellado E. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol 2001, 39:1345-1347.
15. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Denning DW, Cuenca-Estrella M. Inter-laboratory evaluation of haematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol 2003, 41:5236-5237.
16. Chryssanthou E, Cuenca-Estrella M. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect 2006, 12:901-904.
17. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002, 49(suppl 1):7-10.
18. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002, 46:1581-1582.
19. Selcen D, Secmeer G, Aysun S. Mucormycosis in a diabetic child and its treatment with fluconazole: a case report. Turk J Pediatr 1995, 37:165-168.
20. Sica S, Morace G, La Rocca LM. Rhinocerebral zygomycosis in acute lymphoblastic leukaemia. Mycoses 1993, 36:289-291.
21. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother 2001, 48:919-921.
22. Honda A, Kamei K, Unno H, Hiroshima K, Kuriyama T, Miyaji M. A murine model of zygomycosis by Cunninghamella bertholletiae. Mycopathologia 1998, 144:141-146.
23. Ortin X, Escoda L, Llorente A. Cunninghamella bertholletiae infection (mucormycosis) in a patient with acute T cell lymphoblastic leukaemia. Leuk Lymphoma 2004, 45:617-620.
24. Rotowa NA, Shadomy HJ, Shadomy S. In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses 1990, 33:203-211.
25. Zhang R, Zhang JW, Szerlip HM. Endocarditis and haemorrhagic stroke caused by Cunninghamella bertholletiae infection after kidney transplantation. Am J Kidney Dis 2002, 40:842-846.
26. Cagatay AA, Oncu SS, Calangu SS, Yildirmak TT, Ozsut HH, Eraksoy HH. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis 2001, 1:22.
27. Ericsson M, Anniko M, Gustafsson H, Hjalt CA, Stenling R, Tarnvik A. A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis 1993, 16:585-586.
28. Walsh TJ, Hiemenz JW, Seibel NL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396.
29. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998, 26:601-605.
30. Belfiori R, Terenzi A, Marchesini L, Repetto A. Absidia Corymbifera in an immune competent accident victim with multiple abdominal injuries: case report. BMC Infect Dis 2007, 7:46.
31. Kofteridis DP, Karabekios S, Panagiotides JG. Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction. J Chemother 2003, 15:282-286.
32. Jimenez C, Lumbreras C, Aguado JM. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation 2002, 73:476-480.
33. Sungkanuparph S, Sathapatayavongs B, Kunachak S, Luxameechanporn T, Cheewaruangroj W. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases. J Med Assoc Thai 2001, 84:593-601.
34. Nosari A, Oreste P, Montillo M. Mucormycosis in haematologic malignancies: an emerging fungal infection. Haematologica 2000, 85:1068-1071.
35. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
36. Walsh TJ, Chanock SJ. Diagnosis of invasive fungal infections: advances in non-culture systems. Curr Clin Top Infect Dis 1998, 18:101-153.
37. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with haematological diseases?. Leuk Lymphoma 2004, 45:1351-1360.
38. Goldani LZ, Sugar AM. Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug. J Antimicrob Chemother 1994, 33:369-372.
39. Sugar AM, Liu XP. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother 2000, 44:2004-2006.
40. Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses 2004, 47:159-162.
41. Parthiban K, Gnanaguruvelan S, Janaki C, Sentamilselvi G, Boopalraj JM. Rhinocerebral zygomycosis. Mycoses 1998, 41:51-53.
42. Quinio D, Karam A, Leroy JP. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 2004, 42:177-180.
43. Johnson EM, Szekely A, Warnock DW. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998, 42:741-745.
44. Otcenasek M, Buchta V. In vitro susceptibility to nine antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologia 1994, 128:135-137.
45. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998, 41:309-319.
46. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of Zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005, 48:246-250.
47. Dannaoui E, Mouton JW, Meis JF, Verweij PE. Efficacy of antifungal therapy in a non-neutropenic murine model of zygomycosis. Antimicrob Agents Chemother 2002, 46:1953-1959.
48. Mosquera J, Warn PA, Rodriguez-Tudela JL, Denning DW. Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother 2001, 48:583-586.
49. Siwek GT, Dodgson KJ, Magalhaes-Silverman M. Invasive zygomycosis in haematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
50. Trifilio S, Singhal S, Williams S. Breakthrough fungal infections after allogeneic haematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
51. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002, 46:2310-2312.
52. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003, 47:3647-3650.
53. Barchiesi F, Spreghini E, Santinelli A. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007, 51:73-77.
54. Stark D, Milliken S, Marriott D, Harkness J. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. J Med Microbiol 2007, 56:699-701.
55. Rutar T, Cockerham KP. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 2006, 142:187-188.
56. Page RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007, 27:290-298.
57. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998, 30:251-255.
58. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556-1558.
59. Spellberg B, Fu Y, Edwards JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830-832.
60. Reed C, Bryant R, Ibrahim AS. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
61. Dannaoui E, Afeltra J, Meis JFGM, Verweij PE. In vitro susceptibilities of Zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002, 46:2708-2711.
62. Gomez-Lopez A, Cuenca-Estrella M, Mellado E, Rodriguez-Tudela JL. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn Microbiol Infect Dis 2003, 45:199-202.
63. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008, 52:3786-3788.
64. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005, 90:39.